These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12742490)

  • 1. Therapeutic monitoring of sirolimus: its contribution to optimal prescription.
    Holt DW; Denny K; Lee TD; Johnston A
    Transplant Proc; 2003 May; 35(3 Suppl):157S-161S. PubMed ID: 12742490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus: has it gained from experience with older drugs?
    Holt DW
    Therapie; 2002; 57(2):128-32. PubMed ID: 12185960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs.
    Soldin SJ
    Clin Biochem; 1998 Jul; 31(5):381-4. PubMed ID: 9721438
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation.
    Holt DW
    Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):657-63. PubMed ID: 12394613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
    Schachter AD; Benfield MR; Wyatt RJ; Grimm PC; Fennell RS; Herrin JT; Lirenman DS; McDonald RA; Munoz-Arizpe R; Harmon WE
    Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current opinions on therapeutic drug monitoring of immunosuppressive drugs.
    Shaw LM; Holt DW; Keown P; Venkataramanan R; Yatscoff RW
    Clin Ther; 1999 Oct; 21(10):1632-52; discussion 1631. PubMed ID: 10566561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
    MacDonald A; Scarola J; Burke JT; Zimmerman JJ
    Clin Ther; 2000; 22 Suppl B():B101-121. PubMed ID: 10823378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
    Ther Drug Monit; 2003 Aug; 25(4):447-51. PubMed ID: 12883227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation.
    Aspeslet LJ; Yatscoff RW
    Clin Ther; 2000; 22 Suppl B():B86-92. PubMed ID: 10823376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.
    Koster RA; Dijkers EC; Uges DR
    Ther Drug Monit; 2009 Feb; 31(1):116-25. PubMed ID: 19065123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological surrogates of allograft outcome.
    Mahalati K; Kahan BD
    Ann Transplant; 2000; 5(2):14-23. PubMed ID: 11217202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection.
    Holt DW; McKeown DA; Lee TD; Hicks D; Cal P; Johnston A
    Transplant Proc; 2004 Dec; 36(10):3223-5. PubMed ID: 15686732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes.
    Kahan BD; Napoli KL; Podbielski J; Hussein I; Katz SH; Van Buren CT
    Transplant Proc; 2001; 33(1-2):1278. PubMed ID: 11267290
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs.
    Zhang Y; Zhang R
    Drug Test Anal; 2018 Jan; 10(1):81-94. PubMed ID: 28851030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality assessment issues of new immunosuppressive drugs and experimental experience.
    Holt DW; Jones K; Lee T; Stadler P; Johnston A
    Ther Drug Monit; 1996 Aug; 18(4):362-7. PubMed ID: 8857551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.